BiotechTube

bamlanivimab 7000mg + BRII-196+BRII-198 + AZD7442 (IV) + AZD7442 (IM) + SNG001 + Camostat + BMS-986414 + BMS-986413 + SAB-185 (3,840 Units/kg) + SAB-185 (10,240 Units/kg) + CASIRIVIMAB + IMDEVIMAB + Placebo for Bamlanivimab 7000mg + Placebo for Bamlanivimab 700mg + Placebo for BRII-196+BRII-198 + Placebo for SNG001 + Placebo for Camostat + Placebo for SAB-185 (low dose) + Placebo for BMS-986414 + BMS-986413 + Placebo for AZD7442 (IV) + Placebo for AZD7442 (IM) + Placebo for SAB-185 (high dose) + bamlanivimab 700mg

Phase 2/3Completed
1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Coronavirus

Conditions

Coronavirus, Covid19

Trial Timeline

Aug 19, 2020 → Jun 20, 2023

NCT ID
NCT04518410

About bamlanivimab 7000mg + BRII-196+BRII-198 + AZD7442 (IV) + AZD7442 (IM) + SNG001 + Camostat + BMS-986414 + BMS-986413 + SAB-185 (3,840 Units/kg) + SAB-185 (10,240 Units/kg) + CASIRIVIMAB + IMDEVIMAB + Placebo for Bamlanivimab 7000mg + Placebo for Bamlanivimab 700mg + Placebo for BRII-196+BRII-198 + Placebo for SNG001 + Placebo for Camostat + Placebo for SAB-185 (low dose) + Placebo for BMS-986414 + BMS-986413 + Placebo for AZD7442 (IV) + Placebo for AZD7442 (IM) + Placebo for SAB-185 (high dose) + bamlanivimab 700mg

bamlanivimab 7000mg + BRII-196+BRII-198 + AZD7442 (IV) + AZD7442 (IM) + SNG001 + Camostat + BMS-986414 + BMS-986413 + SAB-185 (3,840 Units/kg) + SAB-185 (10,240 Units/kg) + CASIRIVIMAB + IMDEVIMAB + Placebo for Bamlanivimab 7000mg + Placebo for Bamlanivimab 700mg + Placebo for BRII-196+BRII-198 + Placebo for SNG001 + Placebo for Camostat + Placebo for SAB-185 (low dose) + Placebo for BMS-986414 + BMS-986413 + Placebo for AZD7442 (IV) + Placebo for AZD7442 (IM) + Placebo for SAB-185 (high dose) + bamlanivimab 700mg is a phase 2/3 stage product being developed by Eli Lilly for Coronavirus. The current trial status is completed. This product is registered under clinical trial identifier NCT04518410. Target conditions include Coronavirus, Covid19.

What happened to similar drugs?

0 of 12 similar drugs in Coronavirus were approved

Approved (0) Terminated (2) Active (10)
❌Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
❌EQ001 + EQ001 PlaceboBioconPhase 3
🔄Molnupiravir + PlaceboMerckPhase 3
🔄Efprezimod alfa + PlaceboMerckPhase 3
🔄Molnupiravir + PlaceboMerckPhase 3
🔄Canakinumab + PlaceboNovartisPhase 3
🔄anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)PfizerPhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04518410Phase 2/3Completed

Competing Products

20 competing products in Coronavirus

See all competitors
ProductCompanyStageHype Score
COVID-19 VaccineModernaPreclinical
0
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
32
EQ001 + EQ001 PlaceboBioconPhase 3
32
Mesenchymal stem cellRohto PharmaceuticalPhase 1
29
ABBV-47D11 + Placebo for ABBV-47D11 + ABBV-2B04 + Placebo for ABBV-2B04AbbViePhase 1
29
Ibrutinib + PlaceboAbbViePhase 2
35
600 mg AZD7442 IV + 600mg placebo IVAstraZenecaPhase 2
35
EVUSHELDAstraZenecaPre-clinical
26
AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) + AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])AstraZenecaPhase 2
27
AZD7442 IM + Placebo IM + AZD7442 IM + Placebo IM + AZD7442 IV + Placebo IV + AZD7442 IV + Placebo IVAstraZenecaPhase 1
29
Molnupiravir + PlaceboMerckPhase 3
40
Molnupiravir + PlaceboMerckPhase 2/3
38
V590MerckPhase 1
21
Molnupiravir + PlaceboMerckPhase 2/3
30
V591MerckPhase 1/2
24
Efprezimod alfa + PlaceboMerckPhase 3
40
M5049 + M5049 + PlaceboMerckPhase 2
35
Molnupiravir + PlaceboMerckPhase 3
47
Frespaciguat + PlaceboMerckPhase 1
21
Canakinumab + PlaceboNovartisPhase 3
40